Salveo Pharma seeks additional brands in Netherlands

Salveo Pharma  seeks additional brands in  Netherlands
Salveo Pharma plans to expand into Belgium at the start of 2021, says general manager Maurits van Tol

4 November 2020 - Deborah Wilkes

Salveo Pharma is keen to handle additional consumer healthcare brands in its home market of the Netherlands. General manager Maurits van Tol told OTCToolbox that Salveo Pharma would like to hear from companies seeking a distribution partner or with brands for sale.

Van Tol said Salveo Pharma focused on non-prescription medicines, herbal medicines and medical devices, but was not interested in vitamins, minerals and supplements (VMS).

Noting that Salveo Pharma had a strong presence in the cough/cold sector – where it distributes a number of brands for France’s Boiron and Germany’s Engelhard Arzneimittel – van Tol said the company wanted to step into other consumer healthcare categories.

Salveo Pharma was interested in brands with annual sales in excess of EUR1.0 million (USD1.2 million), he added.

Commenting on Salveo Pharma’s approach to business, van Tol said the company “treats distribution brands as though they are our own brands”. “Because we are not that big, we can act very quickly,” he added, noting that a television advertising campaign, for example, could be launched in days rather than weeks.

Founded in 2015, Salveo Pharma is currently only present in the Netherlands but plans to expand into Belgium at the beginning of 2021.

Van Tol said Salveo Pharma generated annual sales of around EUR12.5 million at consumer prices, and had achieved average growth of around 7% per annum over the past five years.

Salveo Pharma distributes brands for Germany’s Engelhard and France’s Boiron

 

The company distributes a number of brands for Engelhard Arzneimittel – including Isla throat pastilles, Nisita nasal ointment, Prospan cough syrup and Trachitol sore-throat lozenges – as well as Boiron’s Oscillococcinum, Cocculine, Coryzalia, Homeovox and Sédatif PC homeopathic medicines.

Van Tol told OTCToolbox that Salveo Pharma aimed to double its annual sales over the next five years. “There is huge potential to develop the existing portfolio in the Netherlands,” he said, adding that the company would “open up Belgium in 2021” and “acquire brands or distribution partners for both countries”.

Salveo Pharma in the Netherlands is a separate company from Salveo Pharma in Central and Eastern Europe and Salveo Pharma in the Middle East and North Africa, although the three companies do cooperate on some projects. They all have their origins as distributors for Engelhard Arzneimittel.

Click here to contact Maurits van Tol by email 

Click here to visit the company's website

Back to Industry News

Share this page: